In a pilot clinical study, the proliferation marker Ki67 was significantly down-regulated in the breast biopsy of BRCA1 mutation carriers who received short-term treatment with denosumab, suggesting that RANKL inhibition appears as a practicable method for the chemoprevention of breast cancer in women with BRCA1 mutations [70,71]. Here, BRCA1 is linked to breast carcinoma.